Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399584 | 1.00 | DGAT1 (0.32) | DGAT1NPC1MAPTPDE4D | |
| SCHEMBL26720567 | 0.78 | HSP90AA1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL15667485 | 0.78 | MAPT (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL29662049 | 0.78 | MAPT (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL26694764 | 0.78 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL30709985 | 0.78 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL30706826 | 0.78 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL24328469 | 0.77 | HSP90AA1 (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL29661419 | 0.77 | HSP90AA1 (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL21369537 | 0.77 | NPC1 (0.31) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | DGAT1 2932/4885NPC1 3807/4885MAPT 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.